Tweet
By Michael Kahn
LONDON (Reuters) - People taking NeuroSearch A/S's obesity pill tesofensine lost twice as much weight as men and women using approved weight loss drugs, Danish researchers said on Thursday.
The study suggest the experimental drug is safe because it had no effect on blood pressure and only raised heart rate slightly, said Arne Astrup of the University of Copenhagen, who led the study published in the journal Lancet.
"It is quite solid from this study that it seems to produce a weight loss that is twice ... what we see from existing compounds on the market," Astrup said in a telephone interview.
The company hopes to take tesofensine to Phase III clinical trials early next year -- the last stage of human testing before a company can seek regulatory approval for a drug.
Full Story: Obesity pill shows promise: study | Health | Reuters
LONDON (Reuters) - People taking NeuroSearch A/S's obesity pill tesofensine lost twice as much weight as men and women using approved weight loss drugs, Danish researchers said on Thursday.
The study suggest the experimental drug is safe because it had no effect on blood pressure and only raised heart rate slightly, said Arne Astrup of the University of Copenhagen, who led the study published in the journal Lancet.
"It is quite solid from this study that it seems to produce a weight loss that is twice ... what we see from existing compounds on the market," Astrup said in a telephone interview.
The company hopes to take tesofensine to Phase III clinical trials early next year -- the last stage of human testing before a company can seek regulatory approval for a drug.
Full Story: Obesity pill shows promise: study | Health | Reuters
Comment